Evaluation of FGF-23 suppressibility by Calcitonin in Healthy Men- pilot study

• Conditions: fysiologische regulatie fosfaat houshouding; phosphate homeostasis; phosphate regulation

• Registration Number: NL-OMON32168
• Lead Sponsor: Rijnstate Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

Healthy, male sex, age 20-55 years

Exclusion Criteria

Serum creatinin > 100 micromol/L, or glomerular filtration rate < 80 ml/min;
Abnormal serum calcium, phosphate, albumin, vitamin D, or PTH level;
Any medication;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>A significant change in de serum FGF-23 levels in response to a single<br /><br>subcutaneous injection of calcitonin 200 IU.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>De serum levels for calcium, parathormon and vitamin D.</p><br>